A Phase II Study of CP-4126 in Patients With Advanced Pancreatic Cancer.

Trial Profile

A Phase II Study of CP-4126 in Patients With Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Gemcitabine elaidate (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Aqualis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2012 Planned number of patients changed from 40 to 120 as reported by European Clinical Trials Database.
    • 09 Feb 2012 Actual patient number (21) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top